June 21, 2010 –  FDA notified healthcare professionals that results from a recent clinical trial raised new concerns about the product’s safety, and the drug failed to demonstrate clinical benefit to patients enrolled in trials. Background: Gemtuzumab Ozogamicin [Mylotarg], indicated …

Gemtuzumab Ozogamicin [Mylotarg]: Market Withdrawal Read more »